Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 826 participants.

Also called NCT07901842

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 826 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07901842
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07901842. Randomized; quadruple masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2029-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence
Acronym
RAISE-AI
Condition
Acute Ischemic Stroke
Intervention (Drug)
Recombinant Human Prourokinase for Injection (rhPro-UK)
Intervention (Drug)
Matching Placebo for Recombinant Human Prourokinase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine (class: other)

Record details

Record id
cardio:ct-nct07901842
Content hash
762548f6c52827b745f4c0b8e64e2fe1c954646fcd7692081a54cce32b46a400